Integrated Diagnostics Holdings

Acquisition And Branch Expansion Will Unlock Middle East Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Apr 25

Updated

11 Dec 25

Views

237

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

52.8%

7D

12.7%

Loading

1Y

52.8%

7D

12.7%

You can edit this narrative until Dec 12 12:10 PM. Then, changes will post as Updates.

Author's Valuation

US$0.814.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

IDHC: Steady Margins And Cash Flows Will Support Share Price Upside

Analysts have modestly adjusted their price target on Integrated Diagnostics Holdings. This reflects a recalibration of valuation multiples and long term growth expectations, while core assumptions on fair value, discount rate, revenue growth, and profit margins remain effectively unchanged.

Shared on 27 Nov 25

Fair value Decreased 1.98%

IDHC: Revenue Expansion Above 30% Will Drive Shares Higher In 2025

Analysts have slightly lowered their price target for Integrated Diagnostics Holdings from $0.82 to $0.80. This change is due to marginal adjustments in fair value estimates as a result of updated financial forecasts.

Shared on 11 Nov 25

IDHC: Revenue Outlook Above 30% Will Support Bullish Momentum

Analysts have modestly raised their price target for Integrated Diagnostics Holdings to $0.82, citing minor adjustments to the discount rate and profit margin expectations. What's in the News Integrated Diagnostics Holdings plc issued new earnings guidance, projecting revenue growth above 30% for the full year 2025 (Key Developments).

Shared on 28 Oct 25

Fair value Increased 0.0044%

Narrative Update on Integrated Diagnostics Holdings Analysts have raised their price target for Integrated Diagnostics Holdings by a marginal amount. This reflects minor upward adjustments in fair value estimates and consistent expectations for revenue growth and profit margin.

Shared on 14 Oct 25

Fair value Increased 20%

Analysts have raised their price target for Integrated Diagnostics Holdings from $0.68 to $0.82, citing improved profit margins and increased fair value estimates. This comes despite a slight dip in projected revenue growth.

Shared on 01 May 25

Fair value Increased 20%

Shared on 23 Apr 25

Fair value Decreased 25%

AnalystConsensusTarget has decreased revenue growth from 19.7% to 13.0% and decreased future PE multiple from 13.6x to 11.8x.

Shared on 17 Apr 25

Fair value Increased 9.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget Fair Value

US$0.8

14.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

15.65%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.07%

Calculation

ج.م2.29b

Earnings '28

x

11.90x

PE Ratio '28

=

ج.م27.19b

Market Cap '28

ج.م27.19b

Market Cap '28

/

581.33m

No. shares '28

=

ج.م46.78

Share Price '28

ج.م46.78 Share Price '28

Discounted to 2025 @ 7.07% p.a.

=

ج.م38.11

Fair Value '25

ج.م38.11 Fair Value '25

Converted to USD @ 0.02103 EGP/USD Exchange Rate

=

US$0.80

Fair Value '25